Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for Merck & Co.
in the ethical pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Reasons to Purchase
- Benchmark Merck & Co.' s performance against key rivals in the ethical
pharmaceutical sector
- Assess the sales growth potential of the key first-in-class drug launches
Januvia and Gardasil
- Analyze Merck & Co.' s continued recovery from the 2004 withdrawal of Vioxx
and 2006 loss of Zocor US patent protection
View Cart
